Defining atherosclerotic plaque biology by mass spectrometry-based omics approaches
Molecular Omics · 2022
DOI: 10.1039/d2mo00260d ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Omics, 2022. Verfasst von Mahesh Chandran und 5 weiteren Autor:innen. Beteiligte Einrichtung: Translational Nanomedicine and Lifestyle Disease Research Laboratory, Department of Biochemistry, University of Kerala, Thiruvananthapuram 695034, Ke…. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Atherosclerosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 145 Literaturangaben.
Abstract (Originalsprache)
Atherosclerosis is the principal cause of vascular diseases and one of the leading causes of worldwide death. Even though several insights into its natural course, risk factors and interventions have been identified, it is still an ongoing global pandemic. Since the structure and biochemical composition of the plaques show high heterogeneity, a comprehensive understanding of the intraplaque composition, its microenvironment, and the mechanisms of the progression and instability across different vascular beds at their progression stages is crucial for better risk stratification and treatment modalities. Even though several cell-based studies, animal studies, and extensive multicentric population studies have been conducted concerning cardiovascular diseases for assessing the risk factors and plaque biology, the studies on human clinical samples are very limited. New novel approaches utilize samples from percutaneous coronary interventions, which could possibly gain more access to clinical samples at different stages of the diseases without complex invasive resections. As an emerging technological platform in disease discovery research, mass spectrometry-based omics technologies offer capabilities for a comprehensive understanding of the mechanisms linked to several vascular diseases. Here, we discuss the cellular and molecular processes of atherosclerosis, different mass spectrometry-based omics approaches, and the studies mostly done on clinical samples of atheroma plaque using mass spectrometry-based proteomics, metabolomics and lipidomics approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Translational Nanomedicine and Lifestyle Disease Research Laboratory, Department of Biochemistry, University of Kerala, Thiruvananthapuram 695034, Kerala, India. janeeshbiochemistry@keralauniversity.ac.in.
- Department of Biotechnology, University of Kerala, Thiruvananthapuram 695034, Kerala, India.
- Mass Spectrometry and Proteomics Core Facility, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, 695012, India.
- Department of Nanoscience and Nanotechnology, University of Kerala, Kariavattom, Thiruvananthapuram-695581, Kerala, India.
- Centre for Advanced Cancer Research, Department of Biochemistry, University of Kerala, Thiruvananthapuram 695034, Kerala, India.
ORCID-Profile: Janeesh Plakkal Ayyappan
Zitieren
APA
Chandran, M., S, S., Abhirami, Chandran, A., Jaleel, A., & Plakkal Ayyappan, J. (2022). Defining atherosclerotic plaque biology by mass spectrometry-based omics approaches. Molecular Omics. https://doi.org/10.1039/d2mo00260d
Vancouver
Chandran M, S S, Abhirami, Chandran A, Jaleel A, Plakkal Ayyappan J. Defining atherosclerotic plaque biology by mass spectrometry-based omics approaches. Molecular Omics. 2022. doi:10.1039/d2mo00260d
BibTeX
@article{Chandran2022,
author = {Chandran, Mahesh and S, Sudhina and Abhirami and Chandran, Akash and Jaleel, Abdul and Plakkal Ayyappan, Janeesh},
title = {Defining atherosclerotic plaque biology by mass spectrometry-based omics approaches},
journal = {Molecular Omics},
year = {2022},
doi = {10.1039/d2mo00260d}
}
EUVIMED